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A B S T R A C T
Foot-and-mouth disease virus (FMDV) is a highly variable RNA virus existing as seven different serotypes. The
antigenic variability between and within serotypes can limit the cross-reactivity and therefore the in vivo cross-
protection of vaccines. Selection of appropriate vaccine strains is crucial in the control of FMD. Determination of
indirect relationships (r1-value) between potential vaccine strains and field strains based on antibody responses
against both are routinely used for vaccine matching purposes. Aiming at the investigation of the repeatability,
reproducibility and comparability of r1-value determination within and between laboratories and serological
tests, a small scale vaccine matching ring test for FMDV serotype A was organized. Well-characterized serum
pools from cattle vaccinated with a monovalent A24/Cruzeiro/Brazil/55 (A24) FMD vaccine with known in vivo
protection status (homologous and heterologous) were distributed to four laboratories to determine r1-values for
the heterologous FMD strains A81/Argentina/87, A/Argentina/2000 and A/Argentina/2001 using the virus
neutralization tests (VNT) and liquid phase blocking ELISA (LPBE). Within laboratories, the repeatability of r1-
value determination was high for both antibody assays. VNT resulted in reproducible and comparable r1-values
between laboratories, indicative of a lack of antigenic relatedness between the A24 strain and the heterologous
strains tested in this work, thus corresponding to some of the in vivo findings with these strains. Using LPBE,
similar trends in r1-values were observed in all laboratories, but the overall reproducibility was lower than with
VNT. Inconsistencies between laboratories may at least in part be attributed to differences in LPBE protocols as
well as the in preexisting information generated in each laboratory (such as antibody titer-protection correlation
curves). To gain more insight in the LPBE-derived r1-values standard bovine control sera were included in the
antibody assays performed in each laboratory and a standardization exercise was performed.
1. Introduction
Foot-and-mouth disease (FMD) remains one of the world's most
important infectious diseases of livestock affecting multiple species of
cloven-hoofed animals (Domingo et al., 2003). The FMD virus (FMDV)
is an aphthovirus within the family of Picornaviridae. To date, seven
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different serotypes have been identified (O, A, C, Asia 1, (Southern
African territories) SAT1, SAT2 and SAT3) and new subtypes arise
frequently (Belsham, 1993). Vaccination is key in the control of FMDV
in both FMD-free and endemic regions (Lubroth et al., 2007). Elim-
ination of FMDV by use of inactivated vaccines has been successful in
Europe and South America (Lombard et al., 2007; Naranjo and Cosivi,
2013). The antigenic variability between and within serotypes however
limits the cross-reactivity of immune responses elicited by one FMDV
strain to another and therefore the probable cross-protection. Thus,
assessing the antigenic and immunogenic relatedness of the vaccine
strain and the field strain as well as matching the vaccine strain with
the circulating field strains is crucial for optimization of vaccination
programs. In addition, it is preferable that vaccines cover a broad an-
tigenic spectrum to increase the level of cross-protection (Paton et al.,
2005). In vivo vaccination-challenge experiments to assess the match
between a particular combination of a vaccine and a field strain are
considered the gold-standard for vaccine matching, but have limita-
tions. In vivo trials need to be conducted in high-containment bio-se-
curity facilities, are labour-intensive and time-consuming resulting in
high expenses. In addition in vivo trials cause suffering of animals and
the outcome is prone to high variability that is seldomly taken into
account (Goris et al., 2007). As a result the number of vaccine matching
tests that can reliably and realistically be performed in vivo, within an
acceptable timeframe in case of an epidemic, is limited. Until today, it is
not possible to predict antigenic differences based on FMDV genomic
sequence data alone (Paton et al., 2005; Ludi and Rodriguez, 2013).
Several papers demonstrate that in vivo protection against FMD strains
homologous to those of the vaccine correlates with antibody titers (Pay
and Hingley, 1986; Van Maanen and Terpstra, 1989; Smitsaart et al.,
1998; Ahl et al., 1983; Periolo et al., 1993; Barnett et al., 2003; Goris
et al., 2008a; Maradei et al., 2008; Willems et al., 2012). This approach,
however, proved more variable for correlations using heterologous
strains and thus alternative serological assays, such as avidity assays
and isotype ELISAs (Lavoria et al., 2012), have also been proposed to
complement classical tests, i.e. virus neutralization tests (VNT) and li-
quid-phase blocking ELISA (LPBE). Despite the limited number of in
vivo experimental cross protection studies correlated with serological
results, in vitro serological methods have been used to estimate the
antigenic and immunogenic differences between FMDV strains and the
outcome of indirect in vitro assays is in general terms comparable to
those observed in vivo (Brehm et al., 2008; Goris et al., 2008b; Maradei
et al., 2011). As a result, in practice vaccine selection is mainly based on
analyses of data from the field (investigations of outbreaks and col-
lection of samples) and in vitro serological vaccine matching tests
(Paton et al., 2005). These in vitro serological tests mainly comprise the
comparison of the serum antibody titers from vaccinated animals [bo-
vine vaccinal serum (BVS)] to the homologous vaccine strain and to
heterologous field strains and the calculation of an indirect relationship
(r1-value) between the strains. However, many variables may affect the
outcome of r1 results and the debate on their interpretation has resulted
in recommendations for determining FMD vaccine strain matching by
serology. These recommendations include the use of VNT and LPBE,
repeated testing, the addition of standardized BVS, the use of serum
pools from at least five vaccinated animals collected 21–30 days after
vaccination and the exclusion of sera with low antibody titers
(Rweyemamu, 1984; Rweyemamu and Hingley, 1984; Paton et al.,
2005; Mattion et al., 2009; OIE - World Organisation for Animal Health,
2019).
To gain further insight into the interpretation of r1-values and to
examine to what extent different laboratories can reproducibly de-
termine r1-values, a small scale vaccine matching ring test for r1-values
with FMDV serotype A was organized using well characterized serum
pools from vaccinated animals with known in vivo protection status. The
present study aimed to investigate (i) the repeatability of r1-value de-
termination within laboratories, (ii) the reproducibility of r1-value de-
termination between laboratories and (iii) the comparability of r1-value
determination based on VNT and LPBE.
2. Material and methods
2.1. Bovine sera and FMDV strains
Serum samples were obtained from a set of ten in vivo tests per-
formed in Argentina following the “Protection against Podal
Generalization” (PPG) protocol. Cattle were one time immunized in-
tramuscularly with a water-in-oil single emulsion vaccine containing
10 μg of inactivated A24/Cruzeiro/Brazil/55 (A24) per dose. The
overall PPG percentage (PPG%), taking into account results of all ten in
vivo tests, when animals were challenged with the homologous A24
strain at 30 days post-vaccination (dpv) was 88.5 %. Sera collected 30
dpv were selected to create three serum pools containing medium
(LPBE titer around 2.5) to high (LPBE titer of at least 3.0) antibody
titers against the homologous A24 strain as determined by LPBE at the
OIE FMD Regional Reference Laboratory located at the National Animal
Health Service (SENASA) in Buenos Aires, Argentina and the Centro de
Virología Animal (CEVAN, Buenos Aires, Argentina) (Mattion et al.,
2009). Pool A consisted of five sera with high homologous antibody
titers. Pool B consisted of five sera with a medium homologous antibody
titers and pool C was made by mixing equal volumes of pool A and pool
B (10 sera) (Table 1). The three serum pools were each further divided
in three aliquots with different labels so in total nine samples (three
replicates of pool A, B and C) were prepared for blind testing by the
participating laboratories. Two standard control bovine sera (SCBS)
derived from animals vaccinated at least three times with a tetravalent
inactivated oil vaccine containing FMDV strains A24, A/Argentina/
2001 (A2001), O1/Campos/Brazil/58 (O1C) and C3/Indaial/Brazil/71
(C3I) and containing high antibody titers against these virus strains
were also included for standardization of the serological assays
(Table 1).
The homologous A24 FMDV strain and the heterologous FMDV
strains A81/Argentina/87 (A87), A/Argentina/2000 (A2000) and
A2001 were provided by SENASA to participating laboratories for use
in the serological assays. The heterologous virus strains were provided
by SENASA in a blinded way. In vivo data indicated that the A24 vaccine
did not induce cross-protection against the heterologous FMDV strains
(PPG≤ 37 %) (Alonso et al., 1987; Smitsaart et al., 2002; Goris et al.,
2008b). An overview of the sera and viruses is given in Table 1.
Table 1
Overview of bovine sera and FMDV strains provided by SENASA to CEVAN, FLI,
Pirbright and CODA-CERVA for blinded interlaboratory r1-value determination.





A24a A2001b O1 Cc C3d
Pool A 1-2-3 3.06 – – – A24 A24
Pool B 4-5-6 2.51 – – – A87e 2
Pool C 7-8-9 2.78 – – – A2000f 3
Control SBCS 1 4.06 4.03 4.34 4.5 A2001 1
SBCS 2 4.22 4.11 4.27 3.93







g Live and binary ethylenimine-inactivated FMDV strains were provided by
SENASA to perform VNT and LPBE, resp.
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2.2. Participating laboratories
Four laboratories participated in the ring trial: (i) Centro de
Virología Animal (CEVAN, Buenos Aires, Argentina) (ii) the Friedrich-
Loeffler-Institut (FLI, Insel-Riems, Germany), (iii) the Pirbright Institute
(Pirbright, UK) and (iv) the Veterinary and Agrochemical Research
Centre (CODA-CERVA, Brussels, Belgium). Each laboratory received the
nine pooled serum samples, live FMDV strains to perform VNT and
binary ethylenimine (BEI)-inactivated FMDV strains to perform LPBE.
The sera and viruses were sent from SENASA to CEVAN and CODA-
CERVA, and from the latter they were further distributed to the FLI and
the Pirbright Institute. All nine pooled serum samples were tested in
each laboratory against the four FMDV strains by VNT and this was
repeated up to nine times, as well as by LPBE and this was repeated
three times.
2.3. Serological assays
2.3.1. Virus neutralization assay
Virus neutralization test were performed according to the OIE
Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (OIE -
World Organisation for Animal Health, 2019) with slight modifications.
At Pirbright VNT were performed on IB-RS2 cells. At SENASA, FLI and
at CODA-CERVA VNT were performed on BHK-21 cells.
2.3.2. Liquid phase blocking ELISA
The LPBE ring trial was performed in two stages. In the first stage all
partner laboratories used their in-house LPBE which was optimized in
terms of antigen concentration and detector monoclonal or guinea-pig
antiserum dilution to obtain an optical density of approximate 1.5 in
the antigen control for the A24 strain. This was done following OIE
methods (OIE - World Organisation for Animal Health, 2019) to im-
prove the detection of antibodies against this strain. In the second stage
the laboratories adjusted in a similar way their LPBE protocol in order
to improve determination of serum antibody titers for the strains A87,
A2000 and A2001 in a blinded way.
2.4. The r1-value determination and interpretation
VNT and LPBE antibody titers obtained in the participating la-
boratories were used to calculate individual r1-values (ri) for each
serum pool at CODA-CERVA using the formula:
ri = 10exp (log10 serum titer against heterologous strain – log10 serum
titer against homologous strain) (1)





m 1 i (2)
Overall mean r1 values were calculated as in (2) with taking into
account the data obtained for all three pools together.
OIE-recommended guidelines were used for the interpretation of the
obtained r1-values. When using VNT, r1-values equal to or above 0.3
indicate a close antigenic relationship between the vaccine strain and
the field isolate and that it is likely that the vaccine strain will confer
cross-protection against the field strain whereas, r1-values less than 0.3
indicate a lack of such cross-protection (Rweyemamu, 1984). When
using LPBE, r1-values between 0.4 and 1.0 are considered indicative of
a close relationship between the vaccine and fields strain under in-
vestigation, i.e. it is considered likely that the vaccine strain will confer
cross-protection against this fields strain; r1-values between 0.2 and
0.39 indicate limited cross-reaction between the vaccine and field
strain, i.e. the vaccine strain might be suitable for use if no closer match
can be found provided that a potent vaccine is used and animals are
vaccinated preferably more than once; and r1-values below 0.2 indicate
a lack of cross-reactivity between the vaccine and field strain, i.e. it is
considered unlikely that the vaccine strain will confer cross-protection
against this fields strain (Ferris and Donaldson, 1992).
2.5. Statistical analyses
The ri and rm-values were compared by analysis of variance (1-way
ANOVA). The rm-values were compared pairwise using the Tukey test.
A value of P≤ 0.05 was considered as the level of significance.
3. Results
In total, 303 individual ri-values were obtained for A87, A2000 and
A2001 using VNT and LPBE.
3.1. Data obtained with VNT
One hundred and ninety-five individual ri-values were obtained by
the four laboratories using the three serum pools: 62 for A87, 62 for
A2000 and 71 for A2001. Mean rm-values obtained with the three
serum pools are shown in Table 2. In all laboratories, all individual ri-
values as well as the upper limit of the 95 % confidence intervals of the
rm were below 0.3, indicating a lack of antigenic relatedness between
the virus strains under investigation and the A24 vaccine strain.
3.2. Data obtained with LPBE
In the first phase, when the LPBE set-up optimized for the homo-
logous A24 strain was used, OD-values obtained in all laboratories with
all three heterologous strains were below the guidance value set by the
OIE (OD ∼1.5) and results could not be validated (OIE - World
Organisation for Animal Health, 2019). In the second phase, when the
Table 2
Mean rm-values and 95 % confidence intervals obtained in the different laboratories for A87, A2000 and A2001 using VNT on the three pools of sera.
Serum Virus Mean rm-value [95%CI]
SENASA / CEVAN FLI PIRBRIGHT CODA-CERVA
Pool A A87 0.03 [0.01; 0.05] 0.11 [0.01;0.21] 0.12 [0.06; 0.17] 0.06 [0.03;0.08]
A2000 0.09 [0.004;0.03] 0.11 [0.03;0.04] 0.10 [0.06; 0.14] 0.1 [0.06;0.15]
A2001 0.007 [0.001;0.01] 0.17 [0.08;0.26] 0.06 [0.05;0.08] 0.07 [0.05;0.1]
Pool B A87 0.01 [0.002;0.02] 0.13 [0.10;0.16] 0.11 [0.08; 0.13] 0.05 [0.02;0.08]
A2000 0.01 [0.003; 0.02] 0.13 [0.13;0.14] 0.01 [0.01; 0.01] 0.06 [0.06;0.09]
A2001 0.01 [0.002;0.02] 0.11 [0.09;0.13] 0.08 [0.02; 0.14] 0.06 [0.05;0.06]
Pool C A87 0.01 [0.003;0.02] 0.16 [0.10;0.23] 0.06 [0.04; 0.09] 0.07 [0.05;0.09]
A2000 0.02 [0.005;0.04] 0.20 [0.12;0.29] 0.07 [0.05; 0.09] 0.04 [0.02;0.07]
A2001 0.01 [0.002;0.02] 0.13 [0.07;0.18] 0.05 [0.04; 0.07] 0.07 [0.05;0.08]
Overall A87 0.07 [0.06;0.08] 0.14 [0.11; 0.16] 0.10 [0.07; 0.12] 0.06 [0.06;0.07]
A2000 0.09 [0.08;0.10] 0.15 [0.11; 0.19] 0.06 [0.03; 0.09] 0.07 [0.05;0.09]
A2001 0.06 [0.05;0.07] 0.14 [0.11; 0.16] 0.06 [0.05; 0.08] 0.06 [0.06;0.07]
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optimized LPBE set-up for the heterologous virus strains was used, 108
ri-values were obtained: 9 for A87, 9 for A2000 and 9 for A2001 in each
laboratory. Results are summarized in Table 3.
In all four laboratories, a pattern of increasing ri-values from A2001
over A87 to A2000 was observed (Fig. 1). In general, the ri-values ob-
tained within the different laboratories were highly repeatable per
sample and per pool. All ri-values obtained at CEVAN were below 0.4 of
which 18 were below 0.2, whereas at FLI all ri-values were above to 0.2
with 25 values being higher than 0.4. With LPBE at Pirbright, 24 ri-
values were below 0.4 of which 19 were below 0.2 and at CODA-CERVA
18 ri-values were below 0.4 of which 9 were below 0.2. At Pirbright, ri-
values for sample 9 (pool C) were consistently above 0.4 for all three
heterologous strains A87, A2000 and A2001, resulting in a lower re-
peatability for pool C compared to pool A and B. At CODA-CERVA ri-
values for A2000 were consistently above 0.4 for all three serum pools.
In all four laboratories ri-values for pool A were generally lower
than those of pool B with values of pool C in between, but these dif-
ferences between pools were not significant. The overall mean r1-values
of all 9 samples (pool A+B+C) for A87 were comparable between
CEVAN, Pirbright and CODA-CERVA. The overall mean r1-values of all
9 samples for A2000 were comparable between FLI and CODA-CERVA
on the one hand and CEVAN and Pirbright on the other hand. The
overall mean r1-values of all 9 samples for A2001 were comparable
between CEVAN and CODA-CERVA, but those of Pirbright and FLI were
significantly different from the three other laboratories. Within la-
boratories, correlations between r1-values obtained by VNT and LPBE
were generally low (Pearson’s correlation coefficient below │0.40│)
except for A87 and A2001 in CEVAN with correlation coefficients of
0.51 and 0.90, resp.
Taking into account the known lack of in vivo cross-protection in-
duced by the A24 vaccine against the heterologous A87, A2000 and
A2001 strains (Alonso et al., 1987; Smitsaart et al., 2002; Goris et al.,
2008b) on the one hand and the observed differences in r1-values de-
termined in the participating laboratories on the other, it was examined
whether LPBE outcomes could be standardized to increase the re-
producibility of r1-value determination between the laboratories.
Standardized bovine control sera (SBCS 1 and 2) were included in
LPBEs performed in each laboratory. In each laboratory and with both
SBCS, the highest LPBE antibody titers were detected against A24 and
the lowest against A2001. This resulted in r1-values for A24 well above
1 when A2001 was considered as homologous strain, whereas low r1-
values were obtained for A2001 when A24 was considered as
Table 3
Mean rm-values and 95 % confidence intervals obtained in the different laboratories for A87, A2000 and A2001 using the optimized LPBE on the three pools of sera.
Serum Virus rm-value [95%CI]
SENASA / CEVAN FLI PIRBRIGHT CODA-CERVA
Pool A A87 0.06 [0.04;0.08] 0.58 [0.57;0.60] 0.19 [0.05;0.32] 0.27 [0.21;0.32]
A2000 0.18 [0.11;0.25] 0.77 [0.64;0.91] 0.26 [0.18;0.34] 1 [1;1]
A2001 0.03.[0.016;0.38] 0.43 [0.36;0.50] 0.20 [0.15;0.25] 0.003 [0.003;0.003]
Pool B A87 0.21 [0.20;0.23] 0.70 [0.66;0.74] 0.14 [0.12;0.17] 0.28 [0.23;0.33]
A2000 0.36 [0.33;0.38] 0.99 [0.86;1.12] 0.14 [0.12;0.17] 0.79 [0.68;0.90]
A2001 0.08 [0.07;0.08] 0.61 [0.58;0.63] 0.12 [0.08;0.17] 0.006 [0.005;0.007]
Pool C A87 0.15 [0.13;0.17] 0.55 [0.46;0.63] 0.31 [0;0.65] 0.30 [0.26;0.33]
A2000 0.36 [0.32;0.39] 0.67 [0.56;0.79] 0.41 [0;0.99] 1 [0.90;1.15]
A2001 0.07 [0.05;0.09] 0.42 [0.32;0.53] 0.32 [0;0.66] 0.004 [0.004;0.004]
Overall A87 0.14 [0.07;0.21] 0.61 [0.54;0.68] 0.21 [0.14;0.28] 0.28 [0.21;0.35]
A2000 0.30 [0.17;0.41] 0.81 [0.69;0.94] 0.27 [0.15;0.40] 0.94 [0.82;1.06]
A2001 0.057 [0:0.13] 0.49 [0.42;0.56] 0.21 [0.14;0.28] 0.04 [0;0.07]
rm-values> 0.4 are marked in bold.
Fig. 1. Distribution of individual ri values obtained by the LPBE optimized in different laboratories for detecting A87, A2000 or A2001 strains using 21 dpv sera from
cattle immunized with a monovalent FMDV A24 vaccine. ○: serum 1, 2 and 3 (pool A); Ж: serum 4, 5 and 6 (pool B); Ж: serum 7, 8 and 9 (pool C).
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homologous strain (Table 4). As with the serum pools, with the SBCSs a
pattern of increasing ri-values from A2001 over A87 to A2000 was
observed in all laboratories when A24 was considered as homologous
strain. The r1-values for A87, A2000 and A2001 with the SBCSs ob-
tained at FLI, Pirbright and CODA-CERVA were comparable to those
obtained with the serum pools. Conversely, r1-values for A87 and
A2000 in the SBCSs at CEVAN were higher than 0.4 with A24 as
homologous strain, unlike with the serum pools.
Using the SBCSs, a baseline for each of the four virus strains was
calculated as the geometric mean of homologous LPBE antibody titers
obtained by all laboratories. Next, factors were calculated for each la-
boratory taking into account the difference between the obtained an-
tibody titer in the SBCSs and the baseline. Using these factors, LPBE
antibody titers against all viruses obtained at FLI as well as those
against A24 and A2001 obtained at Pirbright were adjusted down-
wards. For CEVAN and CODA-CERVA antibody titers against all viruses
as well as those against A87 and A2000 from Pirbright were adjusted
upwards. Fig. 2 shows the resulting ri corrected (ri,c) values. All ri,c-
values obtained at CEVAN and FLI were lower than their corresponding
ri-values, while at Pirbright and CODA-CERVA only those ri,c-values
obtained for A2001 and A2000 were lower than their corresponding ri-
values (Table 5). In total, the number of individual r1-values above 0.4
for A87, A2000 and A2001 strains, decreased from 37 for ri to 28 for ri,c.
The observed change was due to FLI scoring ri,c below 0.4 for A87 and
A2001 strains. In contrast, the adjustment did not alter the r1-value
classification for Pirbright and CODA-CERVA for serum sample 9 to A87
and A2000 or for pool A, B and C to A2000. Within laboratories, cor-
relations between r1 obtained by VNT and LPBE remained low (Pearson
correlation coefficient< 0.40) except for A87 in CEVAN with a corre-
lation coefficient of 0.51.
4. Discussion
In order to allow optimal and rapid selection of the most suitable
FMD vaccine strain at all times, reliable and reproducible estimation of
the antigenic relatedness between FMDV vaccine strains and FMDV
field strains is required. In vitro serological tests that compare the re-
activity of BVS against the homologous vaccine strain and heterologous
field strains have distinct advantages compared to in vivo challenge
tests. Therefore calculation of r1-values based on antibody titers is most
frequently used in practice to support the choice of an appropriate
vaccine strain. In the present study, well characterized serum pools
from vaccinated animals with known in vivo protection status were used
to examine the repeatability of r1-value determination within labora-
tories. The present data show that using the VNT, all laboratories de-
termined consistent r1-values within their laboratory for A87, A2000
and A2001 in the three serum pools from cattle vaccinated with A24.
Similar observations were made for the LPBE, with only one laboratory
obtaining a deviating r1-value for one sample of serum pool C with the
deviation in itself being consistent. Our findings are similar to those of
Mattion et al. (2009) who reported the reducing effect of pooling of
serum samples on the inter-animal and inter-trial variation of calcu-
lated r1-values, especially when sera from in vivo protected animals
were used (Mattion et al., 2009).
The second aim was to examine the reproducibility of r1-value de-
termination between laboratories. Using the VNT, all laboratories
Table 4
Individual ri-values for A24, A87, A2000 and A2001 obtained by the optimized
LPBE in the different laboratories, with either A24 or A2001 as homologous
strains and using standard bovine control sera (SBCS) from cattle immunized
with a tetravalent formulation (A24/O1C/C3I/A2001).
Serum1 Virus ri-value considering A24 as homologous strain/considering





SBCS 1 A24 1/10.68 1/1.96 1/3.74 1/99.61
A87 0.37/3.94 0.69/1.36 0.27/1.00 0.14/14.25
A2000 1.49/15.95 0.83/1.63 0.27/1.00 0.45/45.71
A2001 0.09/1 0.51/1 0.26/1 0.01/1
SBCS 2 A24 1/5.36 1/1.55 1/5.09 1/32.74
A87 0.79/4.22 0.81/1.26 0.20/1.00 0.45/14.67
A2000 2.02/10.81 0.77/1.19 0.20/1.00 1.30/42.71
A2001 0.19/1 0.64/1 0.20/1 0.03/1
Overall A24 1/7.57 1/1.75 1/4.37 1/57.11
A87 0.54/4.07 0.75/1.31 0.23/1.01 0.25/14.46
A2000 0.86/6.52 0.80/1.39 0.23/1 0.77/43.87
A2001 0.13/1 0.57/1 0.23/1 0.02/1
Fig. 2. Distribution of individual ri,c values obtained in different laboratories by LPBE antibody titres scaled to the baseline for A87, A2000 and A2001 strains using
21 dpv sera from cattle immunized with a monovalent FMDV A24 vaccine. ○: serum 1, 2 and 3 (pool A); Ж: serum 4, 5 and 6 (pool B); Ж: serum 7, 8 and 9 (pool C).
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obtained consistent r1-values below 0.3 indicating a lack of relatedness
between the homologous A24 strain and the heterologous strains
(Rweyemamu, 1984). In contrast, r1-values obtained by LPBE antibody
titers presented a lower reproducibility in all samples to all three het-
erologous viruses ranging from all below 0.4 for one laboratory to all
above 0.4 for another laboratory. These data are similar to and sub-
stantiate previous reports on the VNT producing more reproducible
inter-laboratory results for r1-value calculation than LPBE (Mattion
et al., 2009). The observed differences between laboratories with the
LPBE are most likely due to different LPBE protocols that were applied
in the different laboratories, whereas VNT were conducted following
more standardized methodologies. It is well-known that antibody titers
obtained in different laboratories cannot be compared directly (Barnett
et al., 2003; Brehm et al., 2008; Goris et al., 2008a). Although r1-values
represent the ratio of antibody titers against different virus strains ob-
tained within the same laboratory, the differences in LPBE antibody
titers obtained for different FMD virus strains seem to still prevent
immediate comparability of r1-values between laboratories.
The r1-values that corresponded best with the VNT and the in vivo
findings were obtained by use of a LPBE at CEVAN based on trapper and
detector monoclonal antibodies (Mabs) developed against the A24
strain. This assay managed to capture all examined virus strains with an
optimal optical density and without large differences in concentrations
of the reagents. Therefore it represented the blocking reactions with the
different FMDV strains to a similar degree resulting in r1-values that
corresponded well with in vivo and VNT findings. LPBE set up with
polyclonal trapper and/or detector reagents developed against the A24
strain, on the other hand, seem to capture the heterologous virus strains
less efficiently, thus producing higher LPBE antibody titers and re-
sulting in overestimation of r1-values. This seemed the case for all three
heterologous strains at FLI and for A2000 at CODA-CERVA. The order
of magnitude LPBE-derived r1-values obtained for A2001 at CODA-
CERVA are similar to previous findings (Mattion et al., 2009). Inter-
estingly, Mattion et al. (2004) reported the reactivity with a set of Mabs
raised against A24, A87 and an A/Argentina/79 strain, to be lower for
the A2000 strain than for the A2001 and A87 strains (Mattion et al.,
2004). These antigenic characteristics of the A2000 strain may have
contributed to the lower capture efficiency of the A2000 strain in the
LPBE at CODA-CERVA. It should be noted that all LPBE were performed
in a blinded way with the participating laboratories not being aware of
the nature of the serum and the nature of viruses at the time of testing.
This situation would not necessarily reflect a practical situation in
which laboratories would use their knowledge, experience and skills to
optimize test approaches and interpretations. The present findings
however emphasize once more the importance of using optimized and
standardized reagents and methods and the need for consistent testing
conditions to improve the comparability of serological test outcomes
between laboratories.
The third aim was to examine the comparability of r1-value calcu-
lations based on VNT and LPBE assays. Using the VNT, all laboratories
obtained r1-values below the established threshold being indicative of a
lack of antigenic relatedness (Rweyemamu, 1984), and corresponding
to what has been reported from in vivo studies (Alonso et al., 1987,
Smitsaart et al., 2002, Goris et al., 2008a, 2008b). Findings with LPBE
on the other hand were more complex and correlations between r1-
values obtained by VNT and LPBE were low. Although non-neutralizing
antibodies as well as cell-mediated immune mechanisms may also
contribute to protection (Paton et al., 2005), in vitro neutralizing anti-
bodies, which are not necessarily distinguished by LPBE, may be most
relevant to in vivo protection. Moreover, tests like LPBE do not assess
some qualitative aspects such as the affinity of the antibodies, which
may affect in vitro virus neutralization, as early described (Blank et al.,
1972), also correlating to protection in cattle (Steward et al., 1991). It
would be too hasty to conclude from this inter laboratory study that r1-
values obtained by LPBE are not suitable for the assessment of possible
in vivo protection as Maradei et al. (2008) showed that their LPBE can
reliably be used to evaluate the potency of FMD vaccines.
In an attempt to improve the comparability of VNT and LPBE-based
r1-values and the reproducibility of LPBE-based r1-values between la-
boratories, a standardization exercise was conducted using two stan-
dardized polyvalent SBCS. Using a rough and uniform approach of
scaling LPBE antibody titers of all laboratories to a baseline showed that
the overall number of r1-values indicating limited cross-reaction be-
tween A24 and the heterologous strains tested in these assays had in-
creased. LPBE r1-values improved for the initially most deviating r1-
values. This general improvement suggests the usefulness of using
SBCSs to standardize serological tests relating antibody responses be-
tween laboratories. It must however be admitted that the currently used
polyvalent SBCS originating from animals repeatedly vaccinated with a
tetravalent vaccine may not be most ideal for this purpose. The use of a
vaccine containing more than one FMDV subtype as well as the use of
booster vaccinations is known to stimulate a strong immunity resulting
in a broadened spectrum of antibodies (Paton et al., 2005). The use of
well-characterized monovalent sera to each of the virus strains under
examination may be more appropriate in this context. Further, antibody
titers related to protection are often different for different strains. De-
spite both A24 and A2001 being contained in the vaccine administered
to the animals from which the SBCS originated, all laboratories detected
the highest LPBE antibody titers against A24 and the lowest against
A2001. The use of r1-value determination with fixed values for every
virus strain in every laboratory to predict probable cross-protection
may therefore not necessarily be quite appropriate. For improved as-
sessment of the cross-protective potential in each laboratory, it may be
worthwhile investigating settings of r1-value limits depending on virus
Table 5
Mean rm-c values obtained in the different laboratories for A87, A2000 and A2001 using the optimized LPBE on the three pools of sera.
Serum Virus rm,c-value [95%CI]
SENASA / CEVAN FLI PIRBRIGHT CODA-CERVA
Pool A A87 0.04 [0.03;0.07] 0.29 [0.29;0.30] 0.35 [0.24;0.46] 0.39 [0.30;0.46]
A2000 0.12 [0.08;0.17] 0.57 [0.47;0.66] 0.54 [0.37;0.72] 0.74 [0.74;0.74]
A2001 0.02 [0.01;0.03] 0.07 [0.06;0.08] 0.09 [0.06;0.12] 0.01 [0.01;0.01]
Pool B A87 0.14 [0.13;0.16] 0.35 [0.33;0.37] 0.20 [0.16;0.25] 0.40 [0.34;0.48]
A2000 0.24 [0.22;0.26] 0.72 [0.63;0.81] 0.32 [0.26;0.7] 0.59 [0.50;0.67]
A2001 0.05 [0.05;0.06] 0.10 [0.09;0.11] 0.05 [0.04;0.06] 0.03 [0.03;0.04]
Pool C A87 0.10 [0.09;0.12] 0.27 [0.23;0.32] 0.54 [0;1] 0.43 [0.38;0.48]
A2000 0.24 [0.22;0.27] 0.49 [0.41;0.58] 0.84 [0;1] 0.76 [0.67;0.86]
A2001 0.05 [0.04;0.07] 0.07 [0.05;0.09] 0.14 [0;0.31] 0.02 [0.02;0.02]
Overall A87 0.098 [0.068;0.12] 0.31 [0.28;0.33] 0.36 [0.14;0.58] 0.41 [0.37;0.44]
A2000 0.020 [0.12;0.28] 0.59 [0.51;0.67] 0.57 [0.22;0.92] 0.70 [0.59;0.81]
A2001 0.041 [0.030;0.054] 0.081 [0.070;0.10] 0.091 [0.036;0.15] 0.024 [0.018;0.030]
A decrease of rm,c-value compared to the rm-value (Table 2) is marked in bold.
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strains used.
Although the present findings suggest that a solution is not found in
a single approach and that further research is needed, the present study
provides valuable insight and suggests a path to harmonized r1-value
determination in the participating laboratories. Shortly after this inter
laboratory study Lavoria et al. (2012) showed that a combined use of
their newly developed single dilution avidity ELISA with subtyping of
IgG and VNT discriminated better between protected and unprotected
animals than VNT or LPBE alone. It would be interesting to include
these tests in future inter laboratory studies.
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